A new study has revealed that widely prescribed diabetic drug, metformin, could provide health benefits to both type 2 diabetics as well as people without the disease.
The findings indicated that a drug used to control glucose levels in the body and already known to exhibit anticancer properties, could offer prognostic and prophylactic benefits to people without diabetes.
The study also suggested that patients treated with the drug for diabetes type 2 could live longer than people without the condition.
Professor Craig Currie from Cardiff University's School of Medicine said that Patients treated with metformin had a small but statistically significant improvement in survival compared with the cohort of non-diabetics, whereas those treated with sulphonylureas had a consistently reduced survival compared with non-diabetic patients.
He further explained that the findings indicated that this cheap and widely prescribed diabetic drug may have beneficial effects not only on patients with diabetes but also for people without, and people with type 1 diabetes and it also have anti-cancer and anti-cardiovascular disease benefits, in fact it could also reduce pre-diabetics' chances of developing the disease by a third.
It was also suggested that this does not mean that people with type 2 diabetes get off Scott free as their disease would progress, so the best way to avoid the condition altogether would be by keeping moderately lean and taking some regular light exercise.
The study is published in a leading diabetes journal, Diabetes, Obesity and Metabolism.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
